| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/05/2001 | WO2001047899A1 Substituted piperazine derivatives as mtp inhibitors |
| 07/05/2001 | WO2001047898A2 Substituted piperazine derivatives and their use as inhibitors of the microsomal triglyceride transfer protein (mtp) |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047896A1 Benzimidazoles, production thereof and the use thereof as antithrombotic |
| 07/05/2001 | WO2001047893A1 New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias |
| 07/05/2001 | WO2001047892A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | WO2001047891A1 Heterocyclic compounds having sulfonamide groups |
| 07/05/2001 | WO2001047890A1 Quinoline and quinazoline derivatives and drugs containing the same |
| 07/05/2001 | WO2001047887A1 β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS |
| 07/05/2001 | WO2001047886A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | WO2001047885A1 Substituted indole mannich bases |
| 07/05/2001 | WO2001047883A1 Fused-ring compounds and use thereof as drugs |
| 07/05/2001 | WO2001047880A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047878A1 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 07/05/2001 | WO2001047875A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 07/05/2001 | WO2001047874A1 (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| 07/05/2001 | WO2001047866A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047807A1 Method for preparing ortho silicic acid, ortho silicic acid as obtained, and its use |
| 07/05/2001 | WO2001047562A2 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 07/05/2001 | WO2001047561A1 Hyaluronic acid in the treatment of cancer |
| 07/05/2001 | WO2001047560A2 Particulate vitamin composition |
| 07/05/2001 | WO2001047558A1 Nerve protective drugs |
| 07/05/2001 | WO2001047557A1 Oral preparations for diabetes |
| 07/05/2001 | WO2001047551A2 Eliciting antibodies specific for hepatitis c virus (hcv) |
| 07/05/2001 | WO2001047543A2 Activation and inhibition of the immune system |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047532A1 System for stabilizing lacrimal fluid layer |
| 07/05/2001 | WO2001047531A1 Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity |
| 07/05/2001 | WO2001047529A2 Association of deoxyfructosazine and an antidiabetic agonist of the peroxysome proliferator gamma-activated receptor |
| 07/05/2001 | WO2001047528A2 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/05/2001 | WO2001047527A1 Association of deoxyfructosazine and an antidiabetic of the sulphonylurea family |
| 07/05/2001 | WO2001047526A1 Remedies for external use for allergic skin diseases |
| 07/05/2001 | WO2001047525A1 Antipruritic agents for external use |
| 07/05/2001 | WO2001047524A1 Method and composition for the treatment of pain |
| 07/05/2001 | WO2001047523A1 Method and composition for the treatment of pain |
| 07/05/2001 | WO2001047522A2 Association of deoxyfructosazine and an antidiabetic of the biguanide family |
| 07/05/2001 | WO2001047521A1 Use of ketotifen as ophthalmic agent |
| 07/05/2001 | WO2001047520A1 Thiazolidinedione derivatives in treatment of diabetes mellitus of type 2 |
| 07/05/2001 | WO2001047519A1 Powdery biotin preparations |
| 07/05/2001 | WO2001047518A1 Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii |
| 07/05/2001 | WO2001047517A1 Methods for inhibiting mastocytosis |
| 07/05/2001 | WO2001047516A1 Immunosuppressants |
| 07/05/2001 | WO2001047515A1 Use of trimebutine for treating pain |
| 07/05/2001 | WO2001047514A1 Use of hypoglycemic agent for treating impaired glucose metabolism |
| 07/05/2001 | WO2001047513A1 Treatment of hyperproliferative disorders |
| 07/05/2001 | WO2001047511A2 Treatment of drug-resistant human immunodeficiency virus infection |
| 07/05/2001 | WO2001047510A2 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 07/05/2001 | WO2001047509A2 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
| 07/05/2001 | WO2001047508A2 Combination of trimebutine with an opioid analgesic |
| 07/05/2001 | WO2001047507A2 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 07/05/2001 | WO2001047506A2 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 07/05/2001 | WO2001047505A2 Use of azoles for preventing skin cancer |
| 07/05/2001 | WO2001047504A2 β-TUBELIN INHIBITORS AND THEIR USE AGAINST CANCER |
| 07/05/2001 | WO2001047503A1 Transdermal administration of reboxetine |
| 07/05/2001 | WO2001047499A1 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate |
| 07/05/2001 | WO2001047498A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 07/05/2001 | WO2001047497A2 Controlled release pharmaceutical composition containing tramadol hydrochloride |
| 07/05/2001 | WO2001047493A1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 07/05/2001 | WO2001047492A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | WO2001047491A1 Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer |
| 07/05/2001 | WO2001047490A1 Devices for the delivery of drugs having antiprogestinic properties |
| 07/05/2001 | WO2001047469A2 Treatment of ischemic brain injuries with brain targetted antioxidant compounds |
| 07/05/2001 | WO2001047468A2 Association of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase |
| 07/05/2001 | WO2001047451A1 Apparatus and method for delivering compounds to a living organism |
| 07/05/2001 | WO2001012592A3 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 07/05/2001 | WO2001010424A3 Reducing cholesterol oxides using n-3-pufa and vitamin e |
| 07/05/2001 | WO2001002363A3 N-substituted glycine derivatives |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2001000822A3 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 07/05/2001 | WO2001000554A3 Naphthoquinone derivatives and their use in the treatment and control of tuberculosis |
| 07/05/2001 | WO2001000184A3 Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments |
| 07/05/2001 | WO2000078745A3 Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole |
| 07/05/2001 | WO2000078343A3 Method for treating chronic hbv infection |
| 07/05/2001 | WO2000077169A3 (z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors |
| 07/05/2001 | WO2000076552A8 Methods and compositions for control of bone formation via modulation of leptin activity |
| 07/05/2001 | WO2000076464A3 Oxidatively stable, long-chain ethyl ester emollients |
| 07/05/2001 | WO2000074650A3 Implantable gel compositions and method of manufacture |
| 07/05/2001 | WO2000073278A3 5-phenyl-pyrimidine derivatives |
| 07/05/2001 | WO2000068195A3 Substituted pyrrolidines as cell adhesion inhibitors |
| 07/05/2001 | WO2000061622A3 Genes associated with diseases of the kidney |
| 07/05/2001 | WO2000059942A3 Human obesity protein binding protrein-2 homolog and uses thereof |
| 07/05/2001 | WO2000055137A8 Compounds and methods for modulation of estrogen receptors |
| 07/05/2001 | WO2000052134A3 Inhibitors of prenyl-protein transferase |
| 07/05/2001 | WO2000050024A3 Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
| 07/05/2001 | WO2000040247A8 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/05/2001 | WO1999053910A8 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 07/05/2001 | WO1999047135A8 Conjugated linoleic acid compositions |
| 07/05/2001 | US20010007152 Obtained by immunizing transgenic mice which produce human leukocyte antigen (HLA) with tumor-associated antigens and recovering the nucleic acids encoding the T cell receptors from the cytotoxic T lymphocytes; diagnosis and therapy |
| 07/05/2001 | US20010007073 Spine distraction implant and method |
| 07/05/2001 | US20010007031 Enantiomers of 8-aminoquinoline; antiparasitic compounds for treatment or prevention of Pneumocystis carinii pneumonia, toxoplasmosis, malaria, leishmaniasis, or trypsonosomia |
| 07/05/2001 | US20010007025 Antisense modulation of bcl-x expression |
| 07/05/2001 | US20010006989 Pre-polymerization, monomer(s) dissolved in water-miscible aprotic organic solvent forming non-solvent mixture of polymer; prophylactic or curative antibiotics or antiseptic agents |
| 07/05/2001 | US20010006982 Intravesicular instillation of certain homovanilloid compounds to humans experiencing neurogenic urinary dysfunction including urge; effective for those with spinal cord injury and multiple sclerosis; kits; dosage; no burning |
| 07/05/2001 | US20010006981 Compositions containing an antifungal and a cationic agent |
| 07/05/2001 | US20010006980 Administering to a mammal an EP4 receptor subtype agonist, e.g., prostaglandins PGE1 and PGE2; also may include an active bisphosphonate; bone disorders; osteoporosis; Paget's disease; rhumatoid arthritis; hypercalcemia of malignancies |
| 07/05/2001 | US20010006979 Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
| 07/05/2001 | US20010006976 Efficent, notoxic process of making new key intermediate quaternary ammonium salts and 2-oxazolylalkyl sulfide derivatives and avoids the reaction of a-haloketones with an azide followed by reducing the resulting a-aminoketone |
| 07/05/2001 | US20010006975 Raf kinase inhibitors |